TYME Leadership

Steven Hoffman, Co-Founder, Chairman, and Chief Science Officer

Steve Hoffman co-founded TYME and is our Chairman of the board and Chief Science Officer. Steve served as our Chief Executive Officer from March 2015 to November 2020. Mr. Hoffman has over 30 years of experience in biochemistry and physics, and has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in projects related to chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.

RICHIE CUNNINGHAM, Chief Executive Officer

Mr. Cunningham is our Chief Executive Officer as of November 2020 and brings more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular and metabolic diseases. Richie brings to TYME an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a value driven culture.

Mr. Cunningham also brings significant experience in mergers & acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales & marketing. Most recently, Richie served as CEO at Icagen, leading the company through two transformational acquisitions, acquiring assets and talent out of Pfizer and Sanofi. While CEO at Icagen, he successfully negotiated and signed multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation.

Prior to joining Icagen, Mr. Cunningham was an executive with one of the world’s largest pharmaceutical companies, Boehringer Ingelheim, where he held a variety of key strategic and operational roles, including the launch of Boehringer’s first entrance into the oncology market with Gilotrif® (afatinib), an oral tyrosine kinase inhibitor, as a treatment for patients with non-small cell lung cancer.

Jan M. Van Tornout,, MD, MSc, Chief Medical Officer

Dr. Van Tornout brings over 25 years of medical experience in academia and industry, including over 15 years of global drug development in pharmaceutical and biotech settings and encompassing preclinical, IND, FIH, phase II-IV, (s)NDA, BLA, safety, medical affairs, clinical operations and regulatory experience. He has led clinical management and oncology teams at Natera, INOVIO Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb and Amgen. Dr. Van Tornout has also served as a medical strategy consultant for various biotech companies including Cyclacel Pharmaceuticals, GlaxoSmithKline, Puma Biotechnology, Maverick Therapeutics, ERT, Huya Bioscience, and Gradalis. Dr. Van Tornout previously held academic appointments at the University of Southern California (USC) with clinical appointments at Children’s Hospital Los Angeles as attending pediatric hematologist-oncologist. Dr. Van Tornout received his MD from the Katholieke Universiteit Leuven (KUL), Leuven, Belgium, an MS in classical philosophy from KUL, and a BS from the Faculté Notre-Dame de la Paix, Namur, Belgium. He obtained his certification as a paediatrician from the Gasthuisberg University Hospitals, KUL, and subsequently completed his training as a pediatric hematologist-oncologist at Children’s Hospital Los Angeles, USC. He earned an MSc. in applied biometry from USC and completed a post-doctoral fellowship in molecular epidemiology at USC. Subsequently his National Institutes of Health-sponsored laboratory focused on genetic epidemiology of childhood cancer (EWS) and the application of neural networks to the analysis of large pediatric cancer datasets.

Jonathan Eckard,, PH.D., Chief Business Officer

Jonathan Eckard has served as our Chief Scientific Affairs Officer since 2017 and assumed the role of Chief Business Officer in March 2019. Dr. Eckard has over 12 years of financial experience in equity research, bringing to us both important industry insights and comprehensive understanding of the healthcare equity capital markets. From 2016 to 2017, Dr. Eckard was Chief Business and Strategy Officer of SELLAS Life Science, a private oncology-focused biotechnology company. His previous finance roles include equity research analyst roles at Barclays Capital Markets, Citi Capital Markets, Leerink Swann, and HSBC Securities, where he primarily followed small to mid-sized biotechnology companies. Dr. Eckard received a Bachelor of Science degree in Biochemistry from Ohio University, a Master of Science degree in Toxicology and a PhD in Toxicology and Carcinogenesis from New York University School of Medicine.

John Rothman,, PH.D., Executive Vice President of Product Development

Dr. Rothman has more than 30 years of experience in product development across many disciplines and markets. He was a clinical scientist at the pharmaceutical companies, Schering Plough and Roche, where he was also a clinical director for a number of different therapeutic areas and senior director for all of Roche’s data acquisition, statistical analysis and report writing for all experimental and approved drugs in the Roche portfolio. His work on Interferon-α in AIDs-related Kaposi’s Sarcoma resulted in the approval of first recombinant drug and AIDS treatment called Referon-A. Dr. Rothman later held R&D director positions at Roche and was associated with a number of development programs that resulted in marketed drugs, including Rocephin, Coactin, Rimadyl, Larotid, Dalmane, Rimantidine, Gantrisin, Versed and more. Dr. Rothman was later an executive vice president of science and operations at the biotech company, Advaxis, where he was responsible for R&D, toxicology, regulatory, chemistry, data management, manufacturing and intellectual property. Dr. Rothman has since held chief executive roles with several biopharmaceutical companies. Also, previously, during his career, Dr. Rothman filed numerous patents and managed a portfolio of over 80 issued patents and patent applications.

Dr. Rothman attended the Tulane University School of Medicine, where he studied Pharmacology in the laboratory of Dr. Louis Ignarro awarded the Nobel Prize in Medicine in 1998 and conducted his graduate research at the New Orleans VA Hospital in the laboratory of Dr. Andrew Schally awarded the Nobel Prize in Medicine in 1977.

James Biehl, Chief Legal Officer and Secretary

James Biehl has served as our Chief Legal Officer and Secretary since September 2018 and served on our board of directors from 2017 until September 2018. Mr. Biehl has over 29 years of experience as a corporate and securities lawyer representing big pharma, healthcare systems, healthcare consulting firms, and consumer products and medical device companies. His entire career was with the law firm of Drinker Biddle & Reath LLP where he joined the firm in 1989 and was a partner for over 20 years. Mr. Biehl received a Bachelor of Science degree in Industrial Management from Carnegie Mellon University and a Juris Doctor degree from Temple University Beasley School of Law.

Shabnam Stanicky, Clinical Operations Officer

Shabnam Stanicky has served as our Clinical Operations Officer since 2017. Ms. Stanicky has over 16 years of experience in oncology clinical research and experience in overseeing oncology field operations and global project management. From 2008 to 2017, Ms. Stanicky was a Clinical Operations Manager at Quintiles. Prior to joining Quintiles, she held positions of increasing responsibility at Eli Lilly and the John Wayne Cancer Institute. Ms. Stanicky received a Bachelor of Arts degree in Psychology from UCLA and a Master of Science degree in Health Care Management from California State University, Los Angeles.

Barbara C. Galaini, Corporate Controller

Barbara Galaini has served as our Principal Accounting Officer since August 2018 and our Corporate Controller since April 2018. Ms. Galaini has over 25 years of experience in various finance positions in the financial services industry. From 2017 to April 2018, Ms. Galaini was the Chief Accounting Officer of the Americas for Avolon Holdings, a Dublin-based aircraft leasing company. Prior to 2017, she held various positions at CIT, including Chief Financial Officer and Controller of the Commercial Finance business segments, including the healthcare sector, and was the leader of the SEC Reporting Group. Ms. Galaini received a Bachelor of Science degree in Accounting and a Bachelor of Arts degree in American Studies and Economics from Rutgers University and is a Certified Public Accountant.

John Zucaro,, PE, Senior Vice President, CMC

John Zucaro has served as our Senior Vice President – Manufacturing since 2013 and of Tyme’s precursor Luminant Biosciences LLC since 2011. Mr. Zucaro has over 25 years of experience in the pharmaceutical, chemical and defense industries serving in various roles for public, private and startup companies. Mr. Zucaro received a Bachelor of Science degree in Chemical Engineering from Drexel University, a Master of Science degree in Chemical Engineering from Villanova University, a Master in Business Administration in Finance from The Wharton School, University of Pennsylvania, and is a licensed Professional Engineer (Chemical).